🇺🇸 FDA
Pipeline program

CREXONT ER

IPX203-401-23

Approved small_molecule active

Quick answer

CREXONT ER for Parkinson Disease is a Approved program (small_molecule) at Amneal Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
Amneal Pharmaceuticals
Indication
Parkinson Disease
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials